Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization.

摘要: Intraoperative administration of the proteinase inhibitor aprotinin causes reduction in blood loss and homologous requirement patients undergoing cardiac surgery. To ascertain blood-saving effect to obtain further information about mode action, 40 primary myocardial revascularization were randomly assigned receive either or placebo treatment. Aprotinin was given as a bolus 2 x 10(6) kallikrein inactivator units (KIU) before surgery followed by continuous infusion 5 10(5) KIU/h during Additionally, KIU added pump prime. Strict criteria used homogeneous patient selection. Total reduced from 1,431 +/- 760 ml control group 738 411 (P less than 0.05) 838 963 163 308 0.05). In group, 2.3 2.2 U products given, 0.63 0.96 Twenty-five percent 63% did not banked products. The activated clotting time an indicator inhibition contact phase coagulation significantly increased heparinization (141 13 s vs. 122 25 s) remained until heparin neutralized after cardiopulmonary bypass (CPB).(ABSTRACT TRUNCATED AT 250 WORDS)